Impact of post-resistance molecular retesting strategies on treatment timeliness and clinical outcomes in EGFR-mutant advanced NSCLC: a real-world study

Submitted by Anonymous on

ObjectiveTo evaluate the association of ctDNA-based molecular retesting with treatment timeliness and clinical outcomes in patients with advanced EGFR-mutant Abstract Objective: To evaluate the association of ctDNA-based molecular retesting with treatment timeliness and clinical outcomes in patients with advanced EGFR-mutant...

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

Submitted by Anonymous on

These results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Seoul, Republic of Korea. These data were also simultaneously published...

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Submitted by Anonymous on

--Vera Therapeutics, Inc., a commercial-stage biotechnology company, today announced that TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgA nephropathy at risk for disease progression. Topline results from the...

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

Submitted by Anonymous on

--BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced updated data from the ongoing Phase 1/ 2 SOLARA trial of BH-30643 in...

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

Submitted by Anonymous on

--Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate cancer treatments, today announced the presentation of two real-world analyses supporting protein tyrosine kinase 7 as a durable...

Gefitinib-based therapy in refractory hepatocellular carcinoma with EGFR overexpression: a spatial profiling-guided case report

Submitted by Anonymous on

Abstract Current systemic treatments for advanced hepatocellular carcinoma (HCC) such as antiangiogenic targeted therapies, immune checkpoint inhibitors (ICIs), and their combinations have shown benefit, but widespread drug resistance severely limits patient outcomes and underscores an urgent need for effective post-progression...

Prognostic significance of co-expression of c-MET and EGFR in locally advanced and metastatic gastric cancer: a retrospective cohort study

Submitted by Anonymous on

ObjectiveGastric cancer (GC) remains a leading cause of cancer-related mortality globally. While molecular targeted therapies against HER2 and PD-L1 have adv Abstract Objective: Gastric cancer (GC) remains a leading cause of cancer-related mortality globally. While molecular targeted therapies against HER2...

Subscribe to Newsfeed